Clinical trials
Advanced Solid Tumor clinical trials
Below are recruiting advanced solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,391 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06276491RecruitingPhase 1
XmAb541 for advanced solid tumors
This phase 1 trial tests a new drug, XmAb541, for people with advanced solid tumors (ovarian, endometrial, or germ cell tumors) that have not responded to previous treatments. The trial focuses on people whose tumors have a specific protein called CLDN6 and aims to find a safe and effective dose.
Duarte, CaliforniaAges 15 years+ - NCT07410676RecruitingPhase 1/Phase 2
Donor NK cells with IL-15 and pembrolizumab for advanced solid tumors
This trial tests a new type of cell therapy (natural killer cells) made from a donor, combined with low-dose IL-15 (a protein that helps these cells work) and sometimes with pembrolizumab (Keytruda), for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges Any age - NCT07241039RecruitingPhase 1
Study of an oral drug for advanced squamous cell cancers
This study tests an oral drug called ABBV-711, alone or with another drug, for adults with advanced squamous cell cancers of the head, neck, or lung that have stopped responding to standard treatments. It aims to see how safe and effective the drug is.
Duarte, CaliforniaAges 18 years+ - NCT07661459RecruitingPhase 2
Antihistamine and aspirin with immunotherapy for solid tumors
This trial tests whether taking a daily antihistamine (like Claritin) and a daily aspirin alongside your immunotherapy can make the treatment work better. It's for people with solid tumors who are about to start a PD-1 or PD-L1 blocker.
Lexington, KentuckyAges 18–99 - NCT05991583RecruitingPhase 1/Phase 2
IBB0979 for advanced solid tumors that have stopped responding to treatment
This trial tests an experimental drug called IBB0979 for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the right dose and see if the drug can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05877924RecruitingPhase 1
Early-phase study of an injected cancer treatment for advanced tumors
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
Guanzhou, GuangdongAges 18 years+ - NCT05645276RecruitingPhase 1
Study of AK129 for advanced solid tumors
This Phase 1 study tests AK129 in people with advanced cancers that have spread. It looks for a safe dose and early signs the treatment may work, especially for tumors with measurable disease and needed prior treatment options.
Beijing, Beijing MunicipalityAges 18–75 - NCT07043751RecruitingPhase 1
TQB6411 for advanced solid tumors
This trial tests a new drug, TQB6411, for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and effective for different tumor types.
Beijing, Beijing MunicipalityAges 18–75 - NCT07338838RecruitingPhase 1
Testing TQB3142 in advanced tumors
This trial tests a new drug called TQB3142 in people with advanced cancers that have not responded to standard treatments. The goal is to find a safe dose and see how the drug works in the body.
Guangzhou, GuangdongAges 18–75 - NCT06824363RecruitingEarly Phase 1
Intra-tumor injection study for stomach and esophagus cancer with ARID1a mutation
This trial tests a new approach where immune cells are injected directly into the tumor in people with a specific genetic change (ARID1a mutation) in their stomach or esophagus cancer. It aims to see if this treatment can help when used before any other cancer therapy.
Orange, CaliforniaAges 18 years+ - NCT05306132RecruitingPhase 1
Test drug ASKC202 for advanced lung cancer and MET-positive tumors
This Phase 1 trial studies how safe ASKC202 is, what dose is tolerable, and whether it shows early signs of shrinking certain advanced cancers. Depending on your tumor type and prior treatments, ASKC202 may be tested alone or with another drug.
Zhengzhou, HenanAges 18 years+ - NCT07266298RecruitingPhase 1
T-cell therapy for advanced solid tumors
This trial tests a new therapy using your own immune cells, engineered to recognize and attack cancer cells. It is for people with advanced solid tumors who have no other standard treatment options.
Beijing, Beijing MunicipalityAges 18–75 - NCT06223841RecruitingPhase 1/Phase 2
Testing IAP0971 for advanced solid tumors and lung cancer
This trial tests a new drug, IAP0971, in patients with advanced solid tumors or a specific type of lung cancer (non-small cell lung cancer, or NSCLC) that has high PD-L1 levels. It aims to see if the drug can help when standard treatments have stopped working or are not an option.
Beijing, Beijing MunicipalityAges 18–75 - NCT06979674RecruitingPhase 1
ESG406 for advanced solid tumors
This trial tests a new drug called ESG406 in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and helps shrink tumors.
Chongqing, Chongqing MunicipalityAges 18–80 - NCT06414460RecruitingPhase 1/Phase 2
ISM3412 for advanced solid tumors with MTAP deletion
This study tests a new oral drug called ISM3412 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug can shrink tumors or slow their growth.
Denver, ColoradoAges 18 years+ - NCT06823609RecruitingPhase 1
Study of QLS-1304 for advanced solid tumors
This trial tests an experimental drug, QLS-1304, for people with advanced solid tumors that have stopped responding to standard treatment. The goal is to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT04510766Recruiting
Test tumor genetic results to guide early trial treatments
This trial looks at your tumor’s genetic information from stored tissue to help match you to early-phase treatment options. It may help doctors find a therapy that fits your tumor, especially when standard options have limited benefit.
BellinzonaAges 18 years+ - NCT05039632RecruitingPhase 1/Phase 2
NBTXR3 plus radiation with anti-PD-1 for advanced lung or liver cancers
This study tests whether adding NBTXR3 (given into a tumor) and targeted radiation to anti–PD-1/PD-L1 immunotherapy can improve cancer control in advanced cancers that have spread to the lung and/or liver. Participants may be assigned to different radiation approaches to try to trigger tumor shrinkage in both treated and nearby or distant tumor areas.
Houston, TexasAges 18 years+ - NCT06764771RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new investigational drug, BMS-986488, alone or with another drug (adagrasib), for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and works against certain cancers.
Hackensack, New JerseyAges 18 years+ - NCT06077591Recruiting
Genetic and organoid testing to guide cancer treatment
This trial uses advanced testing (genetic sequencing and lab-grown tumor models) to find the best treatment for people with advanced solid tumors that haven't responded to at least one standard treatment. The goal is to personalize therapy based on your tumor's unique features.
Hong Kong, N.T.Ages 18–100 - NCT06687070RecruitingPhase 1
APG-2449 alone or with PLD for advanced cancers
This trial tests a new drug, APG-2449, either alone or with another chemotherapy called PLD (pegylated liposomal doxorubicin). It is for people with advanced solid tumors, including ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is.
Guangzhou, GuangdongAges 18 years+ - NCT06751329RecruitingPhase 1/Phase 2
Study of DM002 for advanced solid tumors
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT04353375RecruitingPhase 2/Phase 3
Study drug for FGFR2-mutated bile duct cancer
This trial tests HMPL-453 to treat advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has an FGFR2 change. It may help shrink tumors or control the disease in people whose cancer has not responded well to prior treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06475937RecruitingPhase 1
DM001 for advanced solid tumors study
This study tests an experimental drug called DM001 for people with certain advanced cancers (breast, lung, stomach, gastroesophageal, or colorectal) that have not responded to or are not helped by standard treatments. The goal is to see if the drug is safe and how it affects the tumors.
Nashville, TennesseeAges 18 years+
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid tumor?
- Yes. Clin2 currently lists 1,391 recruiting advanced solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.